Rubiconmd jobs
1 match, filter-driven and evidence-linked.
Filters
0 active
Remote, hybrid, onsite
State
Shift type
Weekend work
Country
Cover letter
Assessment
Salary type
Equity type
Family-building benefits
Benefit evidence
- posted 156 days ago
Why we showed this
Description: "rubiconmd"Employer: "rubiconmd"+1
Remote From the posting source Healthcare From the posting source - Mid From the posting source Salary not disclosedeConsult Specialist Panel - All (Remote) Remote At RubiconMD, we are always on the lookout for dedicated specialists who are passionate about improving patient care and expanding access to specialty expertise. Even if we do not have an open role at the moment, we encourage you to apply. By submitting your application, you'll be added to our network, and we will reach out to you when a suitable opportunity arises. RubiconMD is an asynchronous web-based electronic consultation (eConsult) platform where primary care clinicians (PCCs) gain access to same-day insights from medical specialists. PCCs use RubiconMD to improve patient care, reduce unnecessary referrals, diagnostics, and procedures, and learn from our community of specialists representing over 30 specialties and 120 subspecialties (including pediatric sub-specialists). We are looking for specialists who are interested in helping us democratize access to specialty expertise for clinicians working in resource limited and cost-sensitive settings. Our specialists spend 1-3 hours per week responding to eConsults. RubiconMD specialists are covered under our standard telehealth malpractice policy and are compensated for each consult they complete. Key responsibilities: - Respond to questions submitted by primary care clinicians on our HIPAA-compliant text-based electronic consultation (eConsult) platform (can respond from a desktop or mobile web browser); - Ensure recommendations are educational, cost-effective, and supported by evidence-based clinical guidelines - Provide follow-up support as needed - Participate in voluntary product interviews to inform new product extensions and platform updates; and - Participate in voluntary projects and activities upon request (e.g. peer review, CME webinars,
-
Director, Portfolio Omnichannel (Lung HCP)
Revolution Medicines - Redwood City, California, United StatesIndexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 179 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Marketing From the posting source - Director Plus From the posting source $211K-$264K From the posting source Equity Inferred from posting 401(k) reportedDirector, Portfolio Omnichannel (Lung HCP) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This newly created role represents a unique opportunity to shape the future of HCP engagement at Revolution Medicines. The Portfolio Omnichannel Strategy & Operations Team is seeking a forward-thinking, digitally fluent marketing operations leader to drive optimal performance while also delivering high-quality customer experiences across our HCP engagement channels. The Director, Portfolio Omnichannel Strategy & Operations (Oncology Lung HCP) is a highly collaborative leader focused on both strategy & execution and is responsible for partnering with Brand & Commercial function Leads in translating oncology brand strategies into high-impact, compliant, and innovative customer engagement experiences. This leader will define and socialize the strategy and approach to successfully pull through Lung's portfolio of customer engagement ambitions (aligned to the brand's strategic imperatives, objectives and key measures). In a fast-paced, growth-stage biotech environment, this role serves as the connector between strategy and execution partnering cross-functionally
-
Director, Medical Science Liaison (AZ, CO, NM, NV)
Revolution Medicines - Remote (United States)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 180 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Healthcare From the posting source - Director Plus From the posting source $236K-$259K From the posting source Equity Inferred from posting 401(k) reportedDirector, Medical Science Liaison (AZ, CO, NM, NV) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in
-
Director, Medical Science Liaison (ND, SD, NE, MO, IA, KS)
Revolution Medicines - Remote (United States)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 180 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Healthcare From the posting source - Director Plus From the posting source $236K-$259K From the posting source Equity Inferred from posting 401(k) reportedDirector, Medical Science Liaison (ND, SD, NE, MO, IA, KS) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence
-
Clinical Program Manager
Revolution Medicines - Redwood City, California, United StatesIndexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 193 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Healthcare From the posting source - Mid From the posting source $143K-$178K From the posting source Equity Inferred from posting 401(k) reportedClinical Program Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is a unique opportunity for a Clinical Operations Professional. As a Clinical Program Manager (CPM), you will be responsible for acting as a central contact for the Clinical Study Team(s) and assist with the execution and management of Revolution Medicines (RevMed) clinical trials. - Adhere to Clinical Standard Operating Procedures (SOP), Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines. - Be a team leader, providing guidance and oversight for the successful management of all aspects of clinical trials within timelines and designated program budgets. - Partner with cross-functional teams to manage, adjust, and revise project timelines and budgets as needed. - Analyze data health metrics to be shared with stakeholders. - Actively partner with cross-functional teams and vendors to drive the query resolution and data listings review process to meet objectives in a timely and efficient process. - Conduct risk
-
Senior Scientist I, Computational Chemistry
Revolution Medicines - Redwood City, California, United StatesIndexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 219 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Engineering From the posting source - Senior From the posting source $149K-$186K From the posting source Equity Inferred from posting 401(k) reportedSenior Scientist I, Computational Chemistry Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated Senior Scientist I to join our dynamic Computational Chemistry team.This position offers an exciting opportunity to drive drug discovery through cutting-edge computational methods, working at the intersection of structural biology, medicinal chemistry, biology, and data science to accelerate the development of transformative therapeutics for patients. As a key contributor in our Computational Chemistry team, you will: - Partner with multidisciplinary, collaborative teams in Discovery Sciences to design, optimize, and accelerate the discovery of novel drug candidates using structure-based computational methods. - Analyze structure-activity relationships (SAR) and make data-driven decisions by systematically following existing SAR trends to guide compound prioritization and design strategies for Ro5 and bRo5 molecules. - Partner closely with Medicinal Chemists to prioritize compound designs both independently and collaboratively, effectively communicating scientific rationale and recommendations to diverse interdisciplinary teams. - Design and implement virtual screening
-
Research Associate II, Proteomics
Revolution Medicines - Redwood City, California, United StatesIndexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 172 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Other - Mid From the posting source $91K-$110K From the posting source Equity Inferred from posting 401(k) reportedResearch Associate II, Proteomics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated and detail-oriented individual to support mass spectrometry-based proteomics workflows. This is an excellent opportunity for an early-career scientist to gain hands-on experience in proteomics within a drug discovery environment. This role will focus on executing established laboratory workflows, maintaining high-quality data standards, and supporting the development of new capabilities within the team. Training will be provided for specialized techniques and instrumentation. In this role, success will come from consistently executing workflows with accuracy, maintaining well-documented experiments, and building technical proficiency over time. As a key member of the Proteomics group within our dynamic Chemical Biology team, you will: - Perform sample preparation for bottom-up proteomics workflows using established protocols with high attention to detail and consistency. - Execute and help improve automated proteomics workflows. - Support routine instrument operation, maintenance and quality control of LC and MS/MS
-
Senior Clinical Program Manager
Revolution Medicines - Redwood City, California, United StatesIndexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 219 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Healthcare From the posting source - Senior From the posting source $164K-$205K From the posting source Equity Inferred from posting 401(k) reportedSenior Clinical Program Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is a unique opportunity for a Clinical Operations Professional. As a Sr. Clinical Program Manager, you will be responsible for acting as a central contact for the Clinical Study Team(s) and assist with the execution and management of Revolution Medicines (RevMed) clinical trials. Responsibilities: - Adhere to Clinical Standard Operating Procedures (SOP), Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines. - Be a team leader, providing guidance and oversight for the successful management of all aspects of clinical trials within timelines and designated program budgets. - Partner with cross-functional teams to manage, adjust, and revise project timelines and budgets as needed. - Analyze data health metrics to be shared with stakeholders. - Actively partner with cross-functional teams and vendors to drive the query resolution and data listings review process to meet objectives in a timely and efficient process. -
-
Associate Director, Medical Lead GI, Japan
Revolution Medicines - Remote (Japan)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026posted 159 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Equity Inferred from posting 401(k) reportedAssociate Director, Medical Lead GI, Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Medical Lead (ML) for Gastrointestinal and Pancreatic cancers (GI). This role will include to develop and execute strategic medical plan including evidence generation, publication, congress activities, and so on, engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and organize medical education, advisory boards, and medical activities in congresses. Reporting to the Head of Japan Medical Affairs, ML is an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. ML will serve as a key strategic person between Revolution Medicines and healthcare professionals in collaboration with MSL team. Within assigned geographic territory, ML will be
-
Director, Medical Science Liaison (Philadelphia, Hershey, NJ, MD, DC)
Revolution Medicines - Remote (United States)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 185 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Healthcare From the posting source - Director Plus From the posting source $236K-$259K From the posting source Equity Inferred from posting 401(k) reportedDirector, Medical Science Liaison (Philadelphia, Hershey, NJ, MD, DC) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved
-
Senior Research Associate, Proteomics
Revolution Medicines - Redwood City, California, United StatesIndexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 172 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Data From the posting source - Senior From the posting source $106K-$126K From the posting source Equity Inferred from posting 401(k) reportedSenior Research Associate, Proteomics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated and detail-oriented individual to support and advance mass spectrometry-based proteomics workflows. This role is well-suited for a scientist with prior industry experience who is excited to apply and expand their expertise in proteomics within a drug discovery environment. This position will involve executing and optimizing laboratory workflows, maintaining high-quality data standards, and contributing to the development of new capabilities within the team. The ideal candidate will demonstrate strong technical proficiency, attention to detail, and the ability to work both independently and collaboratively. In this role, success will come from consistently delivering high-quality, reproducible data, maintaining well-documented experiments, and proactively identifying opportunities to improve workflows and efficiency. As a key member of the Proteomics group within our dynamic Chemical Biology team, you will: - Perform sample preparation for bottom-up proteomics workflows with high attention to detail and reproducibility.
-
Senior Director, Biostatistics, Europe
Revolution Medicines - Remote (Switzerland)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026posted 219 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Data From the posting source - Director Plus From the posting source Salary not disclosed Equity Inferred from posting 401(k) reportedSenior Director, Biostatistics, Europe Remote (Switzerland) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Playing a critical role as a lead statistician for clinical program(s) and the subject matter expert (SME) in Biostatistics within the Quantitative Sciences function, this position is to provide statistical leadership and support for EU access strategies, healthcare technology assessments and regulatory submissions. - Serve as the statistical lead for European access strategies, ensuring alignment between Global Clinical Development, European regulatory (EMA, MHRA, Swissmedic...) and regional/local Market Access needs to support successful European launches in collaboration with global and regional crossfunctional teams. - Partner with Regional and Local Market Access and HEOR functions to design and lead/oversee the execution of statistical analyses required for value dossiers, including PICO, indirect treatment comparisons, network meta-analyses, and RWE generation. - Partner closely with the development statistical lead, provide statistical support for EU regulatory interactions, including EMA Scientific Advice, MAA, Type II variations, and post-authorization commitments. - Ensure statistical methodologies
-
Director, Global Medical Excellence
Revolution Medicines - Basel, Basel-Stadt, SwitzerlandIndexed from Greenhouse Benefit evidence checked Jun 7, 2026posted 192 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Marketing From the posting source - Staff Plus From the posting source Salary not disclosed Equity Inferred from posting 401(k) reportedDirector, Global Medical Excellence Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Director, Global Medical Excellence, supporting the European region to serve as a key scientific and strategic partner to the Head of Global Medical Excellence. This role will help integrate and advance Medical Excellence initiatives across the portfolio for the European region by connecting science, strategy, and execution across the European regional Medical Affairs teams, in collaboration with the global teams. Key Responsibilities - Serve as a scientific thought partner to the Head of Global Medical Excellence, helping translate medical strategy into aligned Medical Excellence priorities. - Connect and integrate scientific themes, data narratives, and strategic objectives across Medical Excellence functions (e.g., publications, content & training, stakeholder engagement, analytics). - Support consistency and quality of scientific messaging and execution across global and regional Medical Affairs activities. Global-Regional Medical Partnership - Act as a key liaison between Global Medical Excellence and regional/local
-
Associate Director, Global Commercialization Systems Enablement
Revolution Medicines - Remote (United States)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 219 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Operations From the posting source - Director Plus From the posting source $186K-$233K From the posting source Equity Inferred from posting 401(k) reportedAssociate Director, Global Commercialization Systems Enablement Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Global Commercialization Systems Enablement is responsible for coordinating and enabling Commercial and Medical Affairs global systems work across markets outside the United States. This role ensures that regional needs are clearly understood, refined, and effectively integrated into established global processes, including launch orchestration, compliance frameworks, software development lifecycle practices, and prioritization governance. For new market launches outside of the United States, this individual will lead the associated Commercial and Medical business systems workstreams, ensuring coordinated planning, readiness, and execution across regional IT teams, global Commercial and Medical solution teams, and enterprise technology teams. The Associate Director adds value by clarifying requirements, identifying cross market commonalities, and reducing discovery work for global delivery teams such as Omnichannel Solutions, Data Solutions, Medical Affairs Solutions, and Field Solutions. The role supports seamless pull through of work into global intake and execution models, helping
-
Senior Director, Medical Affairs, Spain
Revolution Medicines - Remote (Spain)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026posted 201 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Equity Inferred from posting 401(k) reportedSenior Director, Medical Affairs, Spain Remote (Spain) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, General Manager, Spain the Senior Director, Medical Affairs, Spain is the medical leader responsible for defining and executing the local medical strategy for oncology products. This role serves as the medical voice within the spanish Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that Spanish medical considerations are embedded in the regional medical strategy and plans and will partner with the General Manager and crossfunctional teams, as well as the VP, Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the spanish medical team and work closely with the Global and Regional Medical Affairs teams across Med Affairs functions. Responsibilities: - Act as the Medical Affairs lead for Spain, accountable for local medical strategy, execution, and impact
-
Senior Manager, Medical Science Liaison, Japan
Revolution Medicines - Remote (Japan)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026posted 159 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Healthcare From the posting source - Senior From the posting source Salary not disclosed Equity Inferred from posting 401(k) reportedSenior Manager, Medical Science Liaison, Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Medical Science Liaison (MSL). Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Reporting to JP Regional Medical Science Liaison (JPR MSL), MSLs are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence
-
Executive Director, Computational Systems Biology
Revolution Medicines - Redwood City, California, United StatesIndexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 219 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Data From the posting source - Director Plus From the posting source $265K-$331K From the posting source Equity Inferred from posting 401(k) reportedExecutive Director, Computational Systems Biology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As an Executive Director and Head of Research Computational Biology within our Biology Function, the individual will oversee the scientific and strategic direction of systems biology research and preclinical computational biology initiatives. The individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. We are looking for an experienced leader with strong interpersonal skills and an ability to lead a strong and diverse computational biology team. Key aspects of the role include: - Strategic vision and leadership: Develop and implement a long-term strategy for research systems biology and bioinformatic activities to support a growing pipeline of RAS(ON) and novel targeted inhibitors. Lead and supervise
-
Senior Director, Regional Medical Science Liaison Team Lead - West
Revolution Medicines - Remote (United States)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 212 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Operations From the posting source - Director Plus From the posting source $268K-$295K From the posting source Equity Inferred from posting 401(k) reportedSenior Director, Regional Medical Science Liaison Team Lead - West Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Executive Director of Field Medical Affairs, the Sr. Director will manage and coach a lung regional field medical team, oversee the regional field implementation plan and develop, deploy, and monitor key performance indicators and encourage individual professional development goals across the team. You will drive regional thought leader engagement strategy, foster scientific exchange, and lead insight generation strategies. Importantly, you will foster and identify opportunities to collaborate across functions and be instrumental in launch planning and execution. We are seeking a highly motivated and experienced leader to join our team as a Lung Regional Manager of Medical Science Liaisons. Key aspects of this front-line manager role will include: developing, mentoring, and coaching a team of MSL direct reports across approximately one half of the country. Required Skills, Experience and Education: - Collaborates with Field Medical Executive
-
Senior Manager, Sales Operations & Analytics
Revolution Medicines - Remote (United States)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 219 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Sales From the posting source - Senior From the posting source $150K-$189K From the posting source Equity Inferred from posting 401(k) reportedSenior Manager, Sales Operations & Analytics Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager, Sales Operations & Analytics, reporting to the Senior Director, Sales Operations & Analytics, plays a key role in enabling US Commercial field teams to execute with clarity and impact. This leader partners cross-functionally to translate strategy into scalable processes, actionable insights, and effective, pragmatic, high-impact tools that drive alignment and position the field for success. This individual will support seamless, coordinated commercial field enablement through: Field Operations & Governance - Translate commercial strategy into clear, compliant, and executable field processes. - Lead operating cadence, governance forums, and communications to drive alignment and accountability. - Maintain SOPs and field standards to ensure consistent execution. Sales Systems, Territory & Data - Oversee operations and infrastructure of core field enablement systems including CRM, alignment management, roster management, and sales crediting. - Ensure data integrity, system adoption, territory accuracy, and reporting reliability. - Lead
-
Director, Medical Information
Revolution Medicines - Remote (United States)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 219 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Healthcare From the posting source - Staff Plus From the posting source $201K-$251K From the posting source Equity Inferred from posting 401(k) reportedDirector, Medical Information Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated and experienced professional to join our team as a Director of Medical Information. This role focuses on ensuring the delivery of timely, accurate, and evidence-based responses to healthcare professionals (HCPs), patients, and caregivers. As a key member of the Medical Affairs team, you will oversee the creation and management of medical information content, support compendia submissions, and provide Medical Information support at congresses. The ideal candidate is a skilled communicator with a strong scientific background and can manage projects in a dynamic environment. Key Responsibilities: - Lead oversight and performance management of the global Medical Information call center, ensuring all customer inquiries are handled accurately, compliantly and within established timelines. - Maintains and monitors KPIs, and quality metrics, driving continuous improvement to ensure high-quality, consistent inquiry handling. - Prepares and presents regular reports on medical information performance metrics and outcomes to
-
Manager, FP&A, Europe
Revolution Medicines - Basel, Basel-Stadt, SwitzerlandIndexed from Greenhouse Benefit evidence checked Jun 7, 2026posted 164 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Finance From the posting source - Mid From the posting source Salary not disclosed Equity Inferred from posting 401(k) reportedManager, FP&A, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Manager, FP&A Europe will support the Sr Director FP&A Europe in driving financial planning, reporting, business analytics, and operational execution across the European region as the company prepares for commercial growth. Based in Basel, Switzerland, this role will coordinate budgeting and forecasting activities, deliver financial insights, support reporting and planning tools, and help ensure efficient day-to-day finance operations across European affiliates and functions. The ideal candidate is analytical, hands-on, highly organized, and comfortable operating in a fast-paced biotech environment. Support FP&A & Financial Operations - Support annual budget, quarterly forecast, and long-range planning processes across Europe. - Coordinate planning timelines, templates, and data collection with regional stakeholders. - Assist in maintaining European management P&L structures by country, function, and product. - Prepare monthly Actuals vs. Budget / Forecast reporting and variance analyses. - Consolidate and validate financial submissions from affiliates and functions. - Support OpEx
-
Director, Global Pre-Approval Patient Access
Revolution Medicines - Remote (United States)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 173 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Operations From the posting source - Director Plus From the posting source $201K-$251K From the posting source Equity Inferred from posting 401(k) reportedDirector, Global Pre-Approval Patient Access Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director of Global Pre-Approval Patient Access will lead the strategy, design, and execution of global early access programs for Revolution Medicines' pipeline. This role is critical to enabling appropriate patient access to investigational therapies targeting RAS-addicted cancers while ensuring alignment with clinical development/operations, regulatory requirements, and company priorities. This role will report into the Head of Advocacy and Society Engagement and play an integral role in our commitment to supporting appropriate patient access to medicines. - Develop and support global early access strategy aligned with clinical and regulatory milestones; ensure distinction with other patient access initiatives considered or implemented. - Design and implement free of charge named-patient and cohort early access programs globally. - Serve as overall cross-functional leader of the programs, liaising across Clinical, Regulatory, Medical Affairs, Commercial, Legal, Supply Chain, as needed. - Establish governance for global evaluation , and prioritization
-
Senior Director, Medical Affairs, Midsized Markets Europe
Revolution Medicines - Basel, Basel-Stadt, SwitzerlandIndexed from Greenhouse Benefit evidence checked Jun 7, 2026posted 194 days agoWhy we showed this
Title: semantic matchRole: semantic matchUnspecified Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Equity Inferred from posting 401(k) reportedSenior Director, Medical Affairs, Midsized Markets Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, GM, Midsized Markets, the Senior Director, Medical Affairs, Midsize Markets Europe, is the medical leader responsible for defining and executing the medical strategy for oncology products in our portfolio within Midsized markets. This role serves as the medical voice within the Midsized markets Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that Midsized markets medical considerations are embedded in the regional medical strategy and plans and will partner with the Midsized markets country managers and crossfunctional teams, as well as VP Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the Midsized markets medical team and working closely with the Global, Regional, Country Medical Affairs teams across Med Affairs functions. Responsibilities: - Act as
-
Senior Director, Regional Medical Science Liaison Team Lead - East
Revolution Medicines - Remote (United States)Indexed from Greenhouse Benefit evidence checked Jun 7, 2026 Comp disclosed in postingposted 212 days agoWhy we showed this
Title: semantic matchRole: semantic matchRemote From the posting source Data From the posting source - Staff Plus From the posting source $268K-$295K From the posting source Equity Inferred from posting 401(k) reportedSenior Director, Regional Medical Science Liaison Team Lead - East Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Executive Director of Field Medical Affairs, the Sr. Director will manage and coach a lung regional field medical team, oversee the regional field implementation plan and develop, deploy, and monitor key performance indicators and encourage individual professional development goals across the team. You will drive regional thought leader engagement strategy, foster scientific exchange, and lead insight generation strategies. Importantly, you will foster and identify opportunities to collaborate across functions and be instrumental in launch planning and execution. We are seeking a highly motivated and experienced leader to join our team as a Lung Regional Manager of Medical Science Liaisons. Key aspects of this front-line manager role will include: developing, mentoring, and coaching a team of MSL direct reports across approximately one half of the country. Required Skills, Experience and Education: - Collaborates with Field Medical Executive
Take this list with you
Download the 1 matching jobs in any format - read offline, archive, or hand to an AI assistant with your resume to find the best fits.
Or email it to me instead
The AI-ready prompt is a pre-written question you can paste into Claude, ChatGPT, Gemini, or Perplexity along with your resume. We never see your resume; this happens in your AI client of choice.
AI agent reading directly? Same data lives at /api/jobs.json?q=RubiconMD.
See /llms.txt and /api/openapi.json for the full schema.